Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Therapeutics: Farnesoid X receptor (FXR; NR1H4)

Autoimmune disease

INDICATION: Multiple sclerosis (MS)

Mouse studies suggest FXR agonists could help treat MS. In the experimental autoimmune

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE